BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Spyre Therapeutics (NASDAQ: SYRE) and has maintained a price target of $121 for the stock. This endorsement suggests confidence in the company's future performance.